112 related articles for article (PubMed ID: 19768459)
41. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
Schwenkglenks M; Pettengell R; Szucs TD; Culakova E; Lyman GH
J Hematol Oncol; 2010 Aug; 3():27. PubMed ID: 20723212
[TBL] [Abstract][Full Text] [Related]
42. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
43. [The whole dose at once?].
Rodríguez García J; Ramos Ortega FJ; Sandoval Guerra V; García Sanz R
Sangre (Barc); 1996 Jun; 41(3):259. PubMed ID: 8755216
[No Abstract] [Full Text] [Related]
44. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma.
Casey DJ; Kim AY; Olszewski AJ
Am J Hematol; 2012 May; 87(5):521-4. PubMed ID: 22120982
[No Abstract] [Full Text] [Related]
45. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
Hamed RH; Anter AH; Awad IA
Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
[TBL] [Abstract][Full Text] [Related]
46. [Cardiogenic shock during polychemotherapy in a patient with Hodgkin's disease].
Drzewoski J; Chojnowski K; Olszańska-Skorek T; Krykowski E
Kardiol Pol; 1986; 29(8):555-9. PubMed ID: 2435945
[No Abstract] [Full Text] [Related]
47. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.
Anselmo AP; Cartoni C; Bellantuono P; Maurizi-Enrici R; Aboulkair N; Ermini M
Haematologica; 1990; 75(2):155-8. PubMed ID: 1694156
[TBL] [Abstract][Full Text] [Related]
48. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
49. MOPP, ABVD, or both to treat Hodgkin's disease.
Aisenberg AC
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
[No Abstract] [Full Text] [Related]
50. [Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity].
Datsenko PV; Podol'skiĭ PN; Pan'shin GA; Sotnikov VM; Bozhenko VK
Vopr Onkol; 2010; 56(5):571-5. PubMed ID: 21137237
[TBL] [Abstract][Full Text] [Related]
51. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
Bujan L; Walschaerts M; Brugnon F; Daudin M; Berthaut I; Auger J; Saias J; Szerman E; Moinard N; Rives N; Hennebicq S
Fertil Steril; 2014 Sep; 102(3):667-674.e3. PubMed ID: 25044088
[TBL] [Abstract][Full Text] [Related]
52. Primary biliary cirrhosis following chemotherapy for Hodgkin's lymphoma.
Yoneda K; Sugimoto K; Shiraki K; Tanaka J; Beppu T; Fuke H; Yamamoto N; Takei Y
Intern Med; 2008; 47(5):419-20. PubMed ID: 18310974
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
54. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
55. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
[TBL] [Abstract][Full Text] [Related]
56. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
57. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
58. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
59. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
60. [Comparative study of the efficacy of the DBVCy protocol (daunoblastin, bleomycin, vincristine, cytostasan) and the ABVD protocol in advanced Hodgkin's lymphoma. A prospective inter-clinic study within the framework of the Hauptforschungsrichtung Geschwulsterkrankungen].
Höche D; Wutke K; Anger G; Herold M; Kästner R; Stobbe H; Ihle R; Andres J; Raderecht C; Schleusner A
Arch Geschwulstforsch; 1984; 54(4):333-42. PubMed ID: 6208874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
